International Women’s Day serves as a global reminder of the unique health challenges women face throughout their lives. From reproductive health conditions to autoimmune diseases and cardiovascular risks, women experience distinct disease burdens that require gender-specific approaches to prevention, diagnosis, and treatment.
This comprehensive article examines the most common diseases affecting women, their causes, and the critical role of pharmacovigilance in ensuring medication safety. We explore drug-induced conditions that disproportionately affect women, evidence-based treatment strategies, and age-specific preventive measures. Drawing on the latest Global Burden of Disease data (2021) and recent pharmacovigilance research, this article provides healthcare professionals with essential knowledge to optimize women’s health outcomes while maintaining vigilant safety monitoring.
1. Introduction: The Imperative of Gender-Specific Medicine
Women’s health encompasses far more than reproductive medicine. Biological sex differences influence disease susceptibility, drug metabolism, adverse reaction profiles, and therapeutic outcomes. Understanding these differences is not merely academic—it is essential for providing equitable, effective healthcare.
A landmark 24-year pharmacovigilance study published in 2025 analyzing over 243,000 psychiatric inpatients revealed that women have a significantly higher risk of adverse drug reactions (ADRs) compared to men, with a relative risk of 1.25 (95% CI 1.15-1.35) for antidepressant-induced ADRs . This finding underscores the critical importance of sex-aware pharmacovigilance.
This article addresses the most common diseases affecting women across the lifespan, their causes, drug-induced conditions requiring vigilance, treatment approaches, and age-specific preventive measures—all through the lens of pharmacovigilance and evidence-based medicine.
2. The Global Burden of Common Gynecological and Women’s Health Conditions
2.1 Overview of Disease Burden
According to the Global Burden of Disease (GBD) 2021 study, non-neoplastic gynecological diseases affect 1.53 billion women worldwide, representing a 55.3% increase in absolute cases since 1990 . This dramatic rise is primarily driven by population growth (92.0%) and aging (14.2%), partially offset by epidemiological improvements (-6.2%).
2.2 Most Common Non-Malignant Gynecological Conditions
2.3 Gynecological Cancers
2.4 Regional Disparities
The GBD 2021 study reveals significant geographical disparities based on Socio-demographic Index (SDI) :
2.5 Attributable Risk Factors
Global data identifies key modifiable risk factors :
| Risk Factor | Associated Condition | Contribution |
|---|---|---|
| Unsafe sexual behaviors | Cervical cancer deaths | 1% |
| High Body Mass Index (BMI) | Ovarian cancer deaths | 0.09% |
| High BMI | Uterine cancer deaths | 0.34% |
3. Autoimmune Diseases: A Female-Predominant Challenge
Women are disproportionately affected by autoimmune diseases, with conditions like systemic lupus erythematosus (SLE) showing a striking female-to-male ratio ranging from 4:1 to 11:1 .
3.1 Systemic Lupus Erythematosus (SLE)
A comprehensive 2025 scoping review of 81 publications identified significant sex-specific differences in SLE presentation and outcomes :
| Feature | Women | Men |
|---|---|---|
| Age at Onset | Younger | Higher age at onset |
| Autoantibodies | More frequent Ro/SSA autoantibodies | Higher proportion positive for lupus anticoagulant |
| Organ Manifestations | Alopecia, photosensitivity, Raynaud’s phenomenon, osteoporosis | Higher rates of nephritis, serositis, antiphospholipid syndrome |
| Organ Damage | — | Greater renal and cardiovascular damage |
| Complications | — | More severe infections |
| Treatment Patterns | — | More frequent cyclophosphamide; less frequent antimalarials |
| Adherence | Less frequent adherence to azathioprine and mycophenolate | — |
Pharmacovigilance Implication: These sex differences require tailored monitoring strategies. Men with SLE may need closer cardiovascular and renal surveillance, while women require attention to osteoporosis prevention and medication adherence support.
3.2 Autoimmune Addison’s Disease
Autoimmune Addison’s disease (AAD) occurs more commonly in women and is associated with significant reproductive health implications :
| Condition | Prevalence in AAD | General Population Prevalence |
|---|---|---|
| Premature Ovarian Insufficiency (POI) | 6-10% | 1-2% |
Critical Findings:
- One-third of women with AAD who develop POI do so before age 30
- POI onset precedes or is contemporaneous with AAD diagnosis in most cases
- Women with AAD are more likely to use hormone replacement therapy
- Even when POI is excluded, fertility remains significantly reduced
Pathophysiology: Autoimmune-mediated inflammation of ovarian theca cells, with cross-reacting autoantibodies to steroid-producing cells (StCA) playing a key role . Impaired adrenal androgenesis and resulting sex-hormone deficiency contribute to suboptimal follicular development.
4. Pharmacovigilance in Women: Sex Differences in Adverse Drug Reactions
4.1 The Landmark AMSP Study (1993-2016)
A 24-year pharmacovigilance study published in 2025 analyzed 151,426 female and 92,162 male psychiatric inpatients, providing unprecedented insights into sex differences in ADRs .
Overall ADR Incidence
| Population | ADR Incidence | Relative Risk (95% CI) |
|---|---|---|
| Women | 0.85% | 1.25 (1.15-1.35) |
| Men | 0.67% | Reference |
Specific ADRs with Significant Sex Differences
| Adverse Drug Reaction | Women Incidence | Men Incidence | Relative Risk (95% CI) |
|---|---|---|---|
| Edema | 0.055% | 0.009% | 6.31 (3.06-13.04) |
| Hyponatremia | 0.067% | 0.024% | 2.82 (1.78-4.47) |
| Allergic Cutaneous Reactions | 0.057% | 0.034% | 1.71 (1.13-2.57) |
| Sexual Dysfunction | 0.001% | 0.044% | 17.95 (4.39-73.48) higher in men |
ADR Incidence by Antidepressant Class
| Drug Class | Women | Men | Relative Risk (95% CI) |
|---|---|---|---|
| Selective Serotonin Reuptake Inhibitors (SSRIs) | 0.61% | 0.46% | 1.25 (1.04-1.50) |
| Noradrenergic and Specific Serotonergic Antidepressants (NaSSAs) | 0.71% | 0.48% | 1.46 (1.18-1.81) |
| Tricyclic Antidepressants (TCAs) | 1.02% | 0.92% | 1.24 (1.03-1.49) |
Clinical Implications: These findings highlight the importance of considering sex-specific tolerability when prescribing antidepressants. Women may require closer monitoring for edema, hyponatremia, and cutaneous reactions, while men warrant attention to sexual dysfunction.
4.2 Drug-Induced Liver Injury (DILI) in Women
A 2024 case report highlighted a critical drug interaction affecting a 33-year-old woman on ethinyl estradiol/norgestrel who developed severe liver injury six weeks after starting glecaprevir-pibrentasvir (GP) for hepatitis C treatment .
Key Learning Points:
- DILI was likely due to interaction between ethinyl estradiol and GP affecting the cytochrome P450 (CYP450) system
- Patient presented with nausea, vomiting, abdominal pain, and severe pruritus
- Liver function significantly improved after discontinuing GP
- This interaction had not been previously documented in published literature
Pharmacovigilance Message: Healthcare professionals must maintain heightened vigilance for drug-drug interactions in women of reproductive age, particularly those on hormonal contraceptives. Early detection and discontinuation of culprit medications are the mainstay of treatment.
4.3 Drug-Induced Autoimmune Conditions
Several medications can induce autoimmune phenomena that disproportionately affect women:
| Drug-Induced Condition | Common Culprit Drugs | Sex Predilection |
|---|---|---|
| Drug-Induced Lupus | Procainamide, hydralazine, minocycline, TNF inhibitors | More common in women |
| Drug-Induced Autoimmune Hepatitis | Minocycline, nitrofurantoin, methyldopa | Female predominance |
| Drug-Induced Thyroiditis | Interferon-alfa, interleukin-2, amiodarone | More common in women |
5. Treatment Approaches for Common Women’s Health Conditions
5.1 Polycystic Ovary Syndrome (PCOS)
| Treatment Goal | First-Line Options | Monitoring Considerations |
|---|---|---|
| Menstrual irregularities | Combined oral contraceptives | Thrombosis risk assessment; metabolic monitoring |
| Insulin resistance | Metformin | GI side effects; lactic acidosis risk (rare) |
| Infertility | Letrozole, clomiphene citrate | Ovarian hyperstimulation syndrome monitoring |
| Hirsutism | Anti-androgens (spironolactone) | Contraception required due to teratogenicity |
| Weight management | Lifestyle modification ± GLP-1 agonists | Monitor for GI effects; thyroid C-cell tumors (rare) |
Pharmacovigilance Note: Metformin is generally well-tolerated, but women on long-term therapy should have annual vitamin B12 monitoring due to risk of deficiency.
5.2 Endometriosis
| Treatment Goal | Options | Adverse Effect Monitoring |
|---|---|---|
| Pain management | NSAIDs, analgesics | GI bleeding, renal impairment |
| Hormonal suppression | Combined OCs, progestins, GnRH agonists | Bone density (GnRH agonists >6 months), thromboembolism |
| Surgical | Laparoscopic excision | Surgical complications; recurrence risk |
Emerging Therapies: Elagolix (oral GnRH antagonist) requires monitoring for bone mineral density loss, particularly in adolescents and young women.
5.3 Uterine Fibroids
| Approach | Options | Safety Considerations |
|---|---|---|
| Medical | Tranexamic acid (bleeding), NSAIDs (pain) | Thrombosis risk with tranexamic acid |
| Hormonal | Levonorgestrel-IUS, GnRH agonists | Bone density monitoring for prolonged GnRH use |
| Interventional | UAE, myomectomy, hysterectomy | Fertility preservation considerations |
| Newer agents | Ulipristal acetate | Liver function monitoring required (restricted use) |
5.4 Autoimmune Diseases
SLE Treatment Considerations
| Disease Severity | Treatment | Pharmacovigilance Priorities |
|---|---|---|
| Mild | Hydroxychloroquine, NSAIDs | Retinal toxicity (baseline and annual eye exams) |
| Moderate | Corticosteroids, immunosuppressants | Bone density, infection risk, metabolic effects |
| Severe | Cyclophosphamide, mycophenolate, biologics | Malignancy risk, opportunistic infections, organ-specific toxicity |
Sex-Specific Note: Women on cyclophosphamide require counseling about ovarian toxicity and fertility preservation options.
5.5 Cardiovascular Disease in Women
Cardiovascular disease remains the leading cause of death in women globally. Key considerations include:
| Condition | Treatment Considerations | Sex-Specific Notes |
|---|---|---|
| Hypertension | Standard antihypertensives | Women more prone to ACE inhibitor cough; thiazide-induced hyponatremia |
| Dyslipidemia | Statins | Myalgias more common in women; pregnancy category considerations |
| Heart Failure | Guideline-directed therapy | Pregnancy contraindications for certain agents (ACE inhibitors, ARNI) |
6. Age-Specific Preventive Health Measures for Women
The Women’s Preventive Services Initiative’s Well-Woman Chart provides evidence-based recommendations for preventive health services across the lifespan .
6.1 Adolescence (Ages 13-18)
| Domain | Recommendations | Rationale |
|---|---|---|
| Immunizations | HPV vaccine series | Prevent cervical cancer; complete series before sexual debut |
| Screening | Depression screening, iron deficiency risk assessment | Early intervention for mental health; optimize cognitive development |
| Counseling | Healthy weight, physical activity, nutrition | Establish lifelong healthy habits |
| Reproductive Health | Menstrual health education, contraception counseling | Empower informed decision-making |
6.2 Young Adulthood (Ages 19-39)
| Domain | Recommendations | Rationale |
|---|---|---|
| Cervical Cancer Screening | Pap smear every 3-5 years (age 21+) | Early detection of precancerous lesions |
| STI Screening | Annual chlamydia/gonorrhea screening if sexually active | Prevent PID and infertility |
| Contraceptive Counseling | Discuss all options including LARC | Patient-centered family planning |
| Preconception Care | Folic acid supplementation (400-800 mcg daily) | Neural tube defect prevention |
| Cardiovascular Risk Assessment | Baseline BP, lipid profile if indicated | Early identification of risk factors |
6.3 Middle Adulthood (Ages 40-64)
| Domain | Recommendations | Rationale |
|---|---|---|
| Breast Cancer Screening | Mammography every 1-2 years (age 40-49 shared decision; age 50-74 routinely) | Early detection reduces mortality |
| Colorectal Cancer Screening | Colonoscopy or alternative tests (age 45-75) | Prevent and detect colorectal cancer |
| Cardiovascular Risk | Formal risk assessment (ASCVD risk calculator) | Guide statin and antihypertensive therapy |
| Bone Health | Osteoporosis risk assessment; DXA scan at age 65 | Early intervention for bone loss |
| Menopause Management | Discuss symptom management; HRT risk-benefit | Individualized decision-making |
Pharmacovigilance Note: Hormone replacement therapy (HRT) requires careful risk-benefit assessment. Women should be counseled about the small increased risks of breast cancer, thromboembolism, and stroke, balanced against symptom relief and osteoporosis prevention.
6.4 Older Adulthood (Age 65+)
| Domain | Recommendations | Rationale |
|---|---|---|
| Osteoporosis Screening | DXA scan; treat if indicated | Prevent fragility fractures |
| Falls Prevention | Multifactorial risk assessment | Maintain independence; prevent injury |
| Cognitive Screening | Assess for cognitive impairment | Early diagnosis and support |
| Polypharmacy Review | Regular medication reconciliation | Reduce ADR risk; deprescribe when appropriate |
| Cardiovascular Prevention | Continue BP and lipid management | Extend healthy lifespan |
6.5 Pregnancy and Postpartum Considerations
A 2025 review of global regulatory guidance emphasizes the need for harmonized approaches to studying medicine use in pregnancy :
| Phase | Key Considerations | Pharmacovigilance Priorities |
|---|---|---|
| Preconception | Optimize chronic disease management; folic acid supplementation | Document medication exposures; discuss pregnancy plans |
| Antepartum | Use safest effective agents; avoid known teratogens | Report pregnancy exposures to registries |
| Intrapartum | Consider medication effects on labor and delivery | Monitor for neonatal effects |
| Postpartum | Lactation safety; mental health screening | Report lactation-related ADRs |
7. Preventive Lifestyle Interventions
7.1 Omega-3 Fatty Acids for Bone and Cardiovascular Health
A comprehensive review highlights the benefits of omega-3 fatty acids (DHA and EPA) for women’s health :
| Health Domain | Benefit | Mechanism |
|---|---|---|
| Bone Health | Prevents bone decay; augments bone mineralization | Reduces bone resorption |
| Osteoporosis Prevention | Aids bone preservation in elder females at risk | Supports bone density |
| Cardiovascular Protection | Reduces pathological calcification; cardioprotective | Interferes with vascular calcification |
| Breast Health | Prevents breast microcalcification | Blocks osteoblastic potential in breast cancer cells |
Practical Application: Omega-3 supplementation should be considered for:
- Postmenopausal women at risk of osteoporosis
- Cardiac patients for cardioprotection
- Breast cancer patients as adjunctive therapy (may improve survival and bone quality)
7.2 Lifestyle Modification for High-Risk Populations
A randomized controlled trial in BRCA1/2+ breast cancer survivors who underwent risk-reducing salpingo-oophorectomy demonstrated the benefits of a web-based lifestyle modification program :
| Outcome | Intervention Group | Control Group |
|---|---|---|
| Cardiovascular Fitness | Maintained (+1.1%) | Decreased (-4.0%) |
| Whole Body Bone Area | Increased (+0.5%) | Decreased (-0.8%) |
| BMI | Decreased (-4.7%) | — |
| Fat Mass | Decreased (-8.6%) | — |
Conclusion: Lifestyle interventions can mitigate the deleterious cardiovascular and bone outcomes associated with premature surgical menopause in high-risk women.
8. Practical Pharmacovigilance Recommendations for Healthcare Professionals
8.1 Key Questions When Prescribing for Women
8.2 When to Report to Pharmacovigilance Centres
| Situation | Examples |
|---|---|
| Any suspected ADR to a medication in pregnancy | Document exposure timing; report to pregnancy registry |
| Severe reactions more common in women | Severe edema, hyponatremia, cutaneous reactions |
| Unexpected drug interactions | Hormonal contraceptive interactions |
| Drug-induced autoimmune conditions | Drug-induced lupus, hepatitis |
| Lack of therapeutic effect | May indicate pharmacogenomic difference |
8.3 Reporting in Egypt
Healthcare professionals in Egypt can report adverse drug reactions to:
- Egyptian Drug Authority (EDA) – Egyptian Pharmacovigilance Center (EPVC)
- Email: pv.followup@edaegypt.gov.eg
- Hotline: 15301
- Online reporting portal: [EDA website]
9. Future Directions in Women’s Health Pharmacovigilance
9.1 Emerging Research Priorities
9.2 Call for Harmonized Guidance
A 2025 TransCelerate review identified the need for harmonized global guidance on studying medication use in pregnancy and breastfeeding . Current differences between regions create challenges for:
- Planning research programs
- Interpreting study results
- Implementing consistent risk minimization
10. Conclusion: Empowering Women Through Vigilance
International Women’s Day 2026 reminds us that women’s health is not a niche specialty—it is the foundation of family, community, and societal wellbeing. From the 1.53 billion women affected by gynecological conditions worldwide to the millions navigating autoimmune diseases, cancer, and cardiovascular risk, the challenges are immense—but so are the opportunities.
Key Takeaways for Healthcare Professionals:
The Pharmacovigilance Call to Action:
- Ask every woman about pregnancy status, contraceptive use, and previous ADRs
- Monitor closely for sex-specific adverse reactions
- Report all suspected ADRs to national pharmacovigilance centres
- Participate in pregnancy registries when possible
- Advocate for inclusion of women in clinical research
As we celebrate International Women’s Day, let us commit to healthcare that sees women fully, understands them deeply, and protects them vigilantly—through every stage of life.
References
- Tang WZ, et al. The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021. BMC Public Health. 2025;25(1):1894.
- Seifert J, et al. A 24-year pharmacovigilance study on sex differences in adverse drug reactions to antidepressant drugs. Naunyn Schmiedebergs Arch Pharmacol. 2025.
- Phipps MG, et al. Women’s Preventive Services Initiative’s Well-Woman Chart: A Summary of Preventive Health Recommendations for Women. Obstet Gynecol. 2019;134(3):465-469.
- Albrecht K, et al. Sex- and gender-related differences in systemic lupus erythematosus: a scoping review. Rheumatol Int. 2025;45(7):160.
- Sharma T, et al. Omega-3 fatty acids in pathological calcification and bone health. J Food Biochem. 2020;44(8):e13333.
- Alexe A, et al. Points to Consider on the Use of Medicines in Pregnancy Throughout the Product Lifecycle Based on Global Regulatory Guidance. Ther Innov Regul Sci. 2025;59(3):462-470.
- Gu D, et al. Global Burden of Non-Neoplastic Gynecological Diseases in Women: A 32-Year Analysis with Projections to 2100. Am J Prev Med. 2025.
- Wiese J, et al. Glecaprevir-Pibrentasvir and Ethinyl Estradiol-Induced Liver Injury in a Patient Without Cirrhosis. Cureus. 2024;16(6):e61980.
- O’Murchadha L, et al. Female fertility and pregnancy in autoimmune Addison’s disease – a mini review. Front Endocrinol (Lausanne). 2025;16:1510815.
- Sturgeon KM, et al. Commercially available lifestyle modification program: randomized controlled trial addressing heart and bone health in BRCA1/2+ breast cancer survivors after risk-reducing salpingo-oophorectomy. J Cancer Surviv. 2017;11(2):246-255.
